News headlines about Chiasma (NASDAQ:CHMA) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chiasma earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.6287043850235 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Chiasma (NASDAQ CHMA) remained flat at $$1.65 on Monday. The stock had a trading volume of 312,800 shares, compared to its average volume of 85,040. The company has a market cap of $40.23 and a P/E ratio of -1.41. Chiasma has a one year low of $1.25 and a one year high of $2.95.
Separately, ValuEngine raised shares of Chiasma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.